A5036260771- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Adenosine and Purinergic Signaling
- Nanoparticle-Based Drug Delivery
- Cancer Research and Treatments
- Chemokine receptors and signaling
- Diabetes Treatment and Management
- Diabetes Management and Research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Nanoplatforms for cancer theranostics
- Asthma and respiratory diseases
- Biosimilars and Bioanalytical Methods
- Receptor Mechanisms and Signaling
- Immunodeficiency and Autoimmune Disorders
- Diabetes Management and Education
- Nutrition, Genetics, and Disease
- Synthesis and Biological Evaluation
- Click Chemistry and Applications
- Growth Hormone and Insulin-like Growth Factors
- Diabetes and associated disorders
- Complement system in diseases
- Pancreatic function and diabetes
Novo Nordisk (Germany)
2012-2023
Martin Luther University Halle-Wittenberg
2023
Novo Nordisk (Italy)
2021
Biolog (United States)
2018
ChemoCentryx (United States)
2010-2016
Amgen (United States)
2009-2014
Medical University of Silesia
2012
Medical University of Lublin
2012
Nanjing University
2012
Nanjing General Hospital of Nanjing Military Command
2012
Necrotizing and crescentic GN (NCGN) with a paucity of glomerular immunoglobulin deposits is associated ANCA. The most common ANCA target antigens are myeloperoxidase (MPO) proteinase 3. In manner that requires activation the alternative complement pathway, passive transfer antibodies to mouse MPO (anti-MPO) induces model NCGN closely mimics human disease. Here, we confirm importance C5aR/CD88 in mediation anti-MPO-induced report C6 not required. We further demonstrate deficiency C5a-like...
The complement 5a receptor has been an attractive therapeutic target for many autoimmune and inflammatory disorders. However, development of a selective potent C5aR antagonist challenging. Here we describe the characterization CCX168 (avacopan), orally administered inhibitor. blocked C5a binding, C5a-mediated migration, calcium mobilization, CD11b upregulation in U937 cells as well freshly isolated human neutrophils. retains high potency when present blood. A transgenic knock-in mouse model...
Chemokine (C-C motif) receptor 2 (CCR2) is central for the migration of monocytes into inflamed tissues. The novel CCR2 antagonist CCX140-B, which currently in two separate phase clinical trials diabetic nephropathy, has recently been shown to reduce hemoglobin A1c and fasting blood glucose levels type diabetics. In this report, we describe effects compound on glycemic renal function parameters mice. Since CCX140-B a low affinity mouse CCR2, transgenic human knockin mice were generated...
Objectives: Quemliclustat (Q) is a potent, selective, small-molecule inhibitor of soluble and membrane-bound CD73 developed with the aim blocking adenosine-mediated immunosuppression in tumor microenvironment. The analysis objectives were to construct population pharmacokinetic (Pop PK) model for Q conduct simulations recommend an optimal dose Phase 3 (Ph3) study.Methods: PopPK included data from two phase 1 studies cancer patients (ARC-6 ARC-9), one healthy volunteers (HVs) (AB680CSP0001)...
2604 Background: AB928, a selective, small-molecule A 2a R/A 2b R antagonist, potently blocks the immunosuppressive effects of high adenosine concentrations in tumor microenvironment. Preclinically, combining receptor inhibition with either chemotherapy or anti-PD-1 resulted greater control, suggesting AB928 may have additive activity when paired these agents cancer pts. Methods: Three dose-escalation (3+3 design) studies are assessing safety, pharmacokinetics (PK), pharmacodynamics, and...
AB598 is a CD39 inhibitory antibody being pursued for the treatment of solid tumors in combination with chemotherapy and immunotherapy. metabolizes extracellular adenosine triphosphate (eATP), an alarmin capable promoting antitumor immune responses, into adenosine, immuno-inhibitory metabolite. By inhibiting CD39, consumption eATP reduced, resulting proinflammatory milieu which can activate myeloid cells to promote immunity. The preclinical characterization provides mechanistic rationale...
Prostaglandin D2 (PGD2) plays a key role in mediating allergic reactions seen asthma, rhinitis, and atopic dermatitis. PGD2 exerts its activity through two G protein-coupled receptors (GPCRs), prostanoid D receptor (DP or DP1), chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2 DP2). We report the optimization of series phenylacetic acid derivatives an effort to improve dual AMG 009 against DP CRTH2. These efforts led discovery 853...
The aim of this study was to analyse which factors predict the real-world macro-/microvascular event, hospitalisation and death risk in patients with type 2 diabetes mellitus. Furthermore, we aimed investigate whether there exists both an under- over-treatment these patients. We used a German claims/clinical data set covering years 2010–12. Diabetes-related events were defined as (1) macro-, (2) microvascular leading inpatient hospitalisation, (3) other hospitalisations mellitus main...
Hypoglycaemia is a common side effect of insulin therapy in diabetes patients, with negative physical and emotional impacts. Despite this, there are few studies investigating the frequency non-severe hypoglycaemic events from perspective patients real-world setting. We investigated self-reported NSHE levels hypoglycaemia awareness Germany.Respondents > 15 years Type 1 or insulin-treated 2 (receiving basal only, basal-bolus other regimens) were recruited using online panels to complete ≤ 4...
T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) is an receptor on immune cells that outcompetes activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT CD226 regulatory T (Treg) CD8+ tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting to enhance antitumor immunity. To optimize efficacy therapeutic antibodies against TIGIT, it necessary understand IgG Fc (Fcγ) binding...
Drug Prescribing for Patients with Chronic Kidney Disease in General Practice: a Cross-Sectional Study
Sustained treatment adherence, usually over long periods of time, is critical to the success growth hormone (GH) therapy. However, adherence rates are often poor which may result in suboptimal clinical outcomes. The type device used by patients administer their GH can influence adherence. Offering a choice maximizes chance treatment. Multiple factors will patient’s device, depending on individual priorities. This study evaluated most preferred features injection devices parents using...
The following manuscript was published as a Fast Forward article on February 29, 2012: Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y, Zhao BN, Baumgart T, Berahovich R, Ertl LS, Pennell Seitz L, S, Ungashe Wei Johnson D, Boring Tsou C-L, Charo IF, Bekker P, Schall and Jaen JC, Characterization of CCX140-B, an orally bioavailable antagonist the CCR2 chemokine receptor, for treatment type 2 diabetes associated complications. J Pharmacol Exp Ther jpet.111.190918;...
Objective: Human growth hormone (hGH) delivery systems differ in the size of dose increments that can be set by patient, affecting proximity to target (i.e., prescribed) which attained. We investigated differences dosing increment granularity NordiFlex®, FlexPro®, NordiPen® (all multiple devices) and MiniQuick® (single dose) systems.
<b>Background:</b> A retrospective analysis of German general practice data demonstrated that insulin aspart (IA) was associated with a significantly reduced incidence macrovascular events (MVE: stroke, myocardial infarction, peripheral vascular disease or coronary heart disease) vs. regular human (RHI) in type 2 diabetes patients. Economic implications, balanced against potential improvements quality-adjusted life years (QALYs) resulting from lower risks complications IA this setting have...
Abstract TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor that expressed on natural killer (NK) cells, CD8+ T-cells, immunosuppressive regulatory T-cells (Treg). DNAM-1 (DNAX Accessory Molecule-1; CD226) activating found NK monocytes a subset of T-cells. are paired receptors compete for shared ligands CD155 (PVR) CD112 (Nectin-2) by tumor antigen-presenting cells. binding to or results in immune suppression, whereas the same mediates activation. As...